LTA-guided Antiplatelet Therapy in Interventional Treatment of Intracranial Aneurysms

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The use of intracranial stents broadens the indications for endovascular treatment of intracranial aneurysms and improves the cure rate, but it also increases the risk of postoperative ischemic complications in patients. The current standard dual antiplatelet regimen is considered to be an important method to reduce thrombotic events. However, some patients are resistant to antiplatelet drugs and have a high risk of thrombotic events. In actual clinical work, the standards for platelet function testing are not standardized, and the antiplatelet drug adjustment program also lacks norms and consensus. This study carried out a multi-center, prospective cluster randomized controlled study to explore whether the standardized antiplatelet adjustment program guided by LTA detection can reduce the incidence of ischemic events after stent implantation in patients with intracranial aneurysms. Further determine and correct the curative effect of the standardized use of antiplatelet drugs in the treatment of intracranial aneurysm stents, and finally formulate a set of standardized antiplatelet regimens for aneurysm stents.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital
• Collaborators: Beijing Chao Yang Hospital; Chinese PLA General Hospital; Hebei Medical University Third Hospital; Peking University First Hospital; Peking University International Hospital; Tianjin Medical University General Hospital; Xuanwu Hospital, Beijing
• Treatments: Platelet Aggregation Inhibitors

Criteria

Inclusion Criteria:

• Patients with unruptured intracranial aneurysms who received intracranial stenting; ②Standard dual-antibody therapy for at least 5 days before stent implantation; ③Patients aged 18-80;

• on the day of registration patients with a Modified Rankin Score lower than 2; ⑤patients who agree and sign the consent form;.-

Exclusion Criteria:

• Patients with recurrent aneurysms after interventional therapy or clipping therapy; ②Patients with a history of allergy to aspirin, clopidogrel or ticagrelor;

• Patients who used tilofiban prophylactically before surgery; ④Possible active bleeding Patients with high blood pressure, such as symptomatic intracranial hemorrhage or active gastric ulcer; or patients with bleeding tendency or coagulation dysfunction;

• Any abnormal platelet count (normal value is 100-300 × 10^9/L);

• Patients using Anticoagulants; ⑦ Pregnant or lactating women; ⑧ Suffering from liver disease, kidney disease, congestive heart failure, malignant tumors and other malignant diseases.